Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cigarette smoking

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Cigarette smoking. Displaying page 6 of 11.
    EudraCT Number: 2011-005913-35 Sponsor Protocol Number: DB2116132 Start Date*: 2012-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000384-24 Sponsor Protocol Number: DB2114956 Start Date*: 2012-06-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004807-37 Sponsor Protocol Number: B2C111045 Start Date*: 2008-03-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD
    Medical condition: Chronic Pulmonary obstructive Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) DK (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023417-54 Sponsor Protocol Number: DB2113359 Start Date*: 2011-03-23
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001871-35 Sponsor Protocol Number: AC4116136 Start Date*: 2013-03-04
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: AC4116136: A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to flutic...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023418-29 Sponsor Protocol Number: HZC113109 Start Date*: 2011-02-21
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: HZC113109: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/...
    Medical condition: Chronic Obstructive Pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-004801-28 Sponsor Protocol Number: HZC102972 Start Date*: 2013-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation P...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003973-24 Sponsor Protocol Number: ZEP117115 Start Date*: 2013-01-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Multicenter Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily with Tiotropium 18 mcg Once Daily over 24 Weeks in Subjects with Chronic Obstructive Pulmonar...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000884-42 Sponsor Protocol Number: 201316 Start Date*: 2014-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001150-33 Sponsor Protocol Number: 207609 Start Date*: 2018-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (b...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014551-80 Sponsor Protocol Number: 1268.16 Start Date*: 2010-01-21
    Sponsor Name:BOEHRINGER ING.
    Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb...
    Medical condition: patients with symptomatic asthma on inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004548-44 Sponsor Protocol Number: 200820 Start Date*: 2014-05-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Dai...
    Medical condition: Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000106-24 Sponsor Protocol Number: RAA2006/004 Start Date*: 2006-06-26
    Sponsor Name:Kings College London (IOP)
    Full Title: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact upon adherence
    Medical condition: Smoking addiction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000885-23 Sponsor Protocol Number: 201315 Start Date*: 2014-07-28
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004287-23 Sponsor Protocol Number: P04592 Start Date*: 2006-12-05
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016732-12 Sponsor Protocol Number: MAP0004-CL-P203 Start Date*: 2010-01-21
    Sponsor Name:MAP Pharmaceuticals, Inc.
    Full Title: An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004...
    Medical condition: migraine
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-007056-18 Sponsor Protocol Number: 3403 Start Date*: 2007-03-16
    Sponsor Name:The Newcastle upon tyne Hospitals NHS Trust
    Full Title: The Discoid Lupus Research Project
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001827-38 Sponsor Protocol Number: DB2116961 Start Date*: 2014-08-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) RO (Completed) HU (Completed) SK (Completed) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002304-16 Sponsor Protocol Number: 130873-2004 Start Date*: 2005-06-14
    Sponsor Name:South Tees Hospitals NHS Foundation Trust
    Full Title: The STARS (STeroids Against Re-Stenosis) Trial [THE USE OF Peri-PROCEDURAL ORAL CORTICOSTERIODS TO PREVENT IN-SEGMENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION.]
    Medical condition: coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002769-18 Sponsor Protocol Number: MKC101614 Start Date*: 2005-05-03
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steadystate pharmacokinetics of SB-681323 7.5 mg per day in patients wi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 00:44:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA